The blockbuster diabetes drug Avandia is likely to be sold in a strikingly different way, even if the U.S. Food and Drug Administration chooses to keep it on the market, as a majority of expert panelists have recommended.
The FDA advisory panel voted 20-12 today to recommend keeping the controversial treatment on the market but 17 voted in favor of stricter warning labels or restrictions on its sale. Only three voted not to change the existing warning.
One member abstained from voting. No...Full Story